Clinical Textbook of Addictive Disorders 3rd ed - R. Frances, S. Miller, A. Mack (Guilford, 2005) WW

8. Marijuana, Hallucinogens, and Club Drugs 179Grinspoon L., & Bakalar, J. B. (1995). Marijuana as medicine: A plea for reconsideration.JAMA, 273, 1875–1876.Hampton, R. Y., Medzihradsky, F., Woods, J. H., & Dahlstrom, P. J. (1982). Stereospecificbinding of 3 H phencyclidine in brain membranes. Life Sci, 30, 2147–2154.Hechler, V., Goebaille, S., & Maitre, M. (1992). Selective distribution pattern ofgamma-hydroxybutyrate receptors in the rat forebrain and mid-brain as revealedby quantitative autoradiograph. Brain Res, 572, 345–348.Hepler, R. S., & Petrus, R. J. (1976). Experiences with administration of marijuana toglaucoma patients. In S. Cohen & R. C. Stillman (Eds.), The therapeutic potential ofmarijuana (pp. 63–75). New York: Plenum Medical Books.Hermle, L., Spitzer, M., Borchardt, D., Kovar, K. A., & Gouzoulis, E. (1993). Psychologicaleffects of MDE in normal subjects. Neuropsychopharmacology, 8, 171—176.Holland, J. (2001). Ecstasy: The complete guide. Rochester, VT: Panic Street Press.Holmes, S. B., Banerjee, A. K., & Alexander, W. D. (1999). Hyponatremia and seizuresafter ecstasy use. Postgrad Med J, 75, 32–43.Iversen, L. L., & Snyder, S. H. (1999). The science of marijuana. New York: Oxford UniversityPress.Jansen, K. (1990). A review of the non-medical uses of ketamine: Use, uses, and consequences.J Psychoactive Drugs, 32, 419–433.Johnson, L. D., O’Malley, P. M., & Bachman, J. G. (2002). Monitoring the future nationalresults on adolescent drug use: Overview of key findings, 2001 (NIH Publication No.02-5105). Bethesda, MD: National Institute on Drug Abuse.Kassirer, J. P. (1999). Should medical journals try to influence political debates? N EnglJ Med, 340, 466–467.Khalant, H. (2001). The pharmacology and toxicology of “Ecstasy” (MDMA) andrelated drugs. Can Med Assoc J, 165, 917–928.Koesters, S. C., Rogers, P. D., & Rajasingham, C. R. (2002). MDMA (“Ecstasy”) andother “club drugs”: The new epidemic. Pediatr Clin North Am, 49, 415–433.Kris, M. G., Cubeddu, L. X., Gralla, R. J., Cupissol, D., Tyson, L. B., Venkatraman, E.,& Homesley, H. D. (1996). Are more antiemetic trials with a placebo necessary?:Report of patient data from randomized trials of placebo antiemetics withcisplatin. Cancer, 78, 2193–2198.Krystal, J. H., Karper, L. P., Seibyl, J. P., Freeman, G. K., Delaney, R., Bremner, J. D.,et al. (1994). Subanesthetic effects of the noncompetitive NMDA antagonistketamine in humans. Arch Gen Psychiatry, 51, 199–214.Lammers, G. J., Arends, J., Declerck, A. C., Ferrari, M. D., Schouwink, G., & Troost, J.(1993). Gammahydroxybutyrate and narcolepsy: A double blind placebo controlledstudy. Sleep, 16, 216–220.Lee, S., & McDowell, D. M. (2003). Polysubstance use (GHB, MDMA, and other clubdrugs) by circuit party attendees. Am J Addictions, 181–186.Leister, M. P., Grob, C. S., Bravo, G. L., & Walsh, R. N. (1992). Phenomenology andsequelae of 3,4-methylenedioxymethamphetamine use. J Nerv Ment Dis, 180, 345–354.Li, J., Stokes, S., & Woeckener, A. (1998). A tale of novel intoxication: A review ofthe effects of gamma-hydroxybutyric acid with recommendations for management.Ann Emerg Med, 31, 729–736.Lilly, J. C. (1978). The scientist: A novel autobiography. New York: Lippincott.